Previous close | 0.8901 |
Open | 0.9260 |
Bid | 0.0000 x 1800 |
Ask | 0.0000 x 4000 |
Day's range | 0.8900 - 0.9400 |
52-week range | 0.8200 - 2.1000 |
Volume | |
Avg. volume | 66,500 |
Market cap | 56.081M |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4900 |
Earnings date | 19 Aug 2024 - 23 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 25 Mar 2022 |
1y target est | 5.04 |
Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today reported revenues of US$39.8 million; a basic and diluted net loss per share of US$0.06; and a basic and diluted net loss per ADS of US$0.23 for the first quarter ended March 31, 2024; adjusted basic and diluted net loss per share of US$0.05; and adjusted basic and diluted net loss per ADS of US$0.19. Each ADS represents four Class A ordinary shares.
Zepp Health Corporation ("Zepp Health") (NYSE: ZEPP), a global leader in smart wearables and health technology, proudly announces Amazfit as the Official Sponsor of the Escape from Alcatraz Triathlon (EFAT) which takes place annually in San Francisco. Zepp Health's Amazfit has been working with EFAT since 2022, reinforcing its commitment to supporting the triathlete communities.
Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is below compliance standards due to the trading price of Zepp's American depositary shares (the "ADSs").